Course Objective
- Explain regulatory updates regarding buprenorphine treatment during a public health emergency
- Describe practice-level changes in buprenorphine treatment throughout COVID-19
- Discuss common issues affecting patients in buprenorphine treatment during COVID-19
Date: July 7th, 2020
Presenter:
Tiffany Lu, MD, MS
Assistant Professor of Medicine
Montefiore Medical Center / Albert Einstein School of Medicine
In this month’s Log-in2Learn Dr. Tiffany Lu provides an overview of buprenorphine treatment prior to the COVID-19 pandemic and the challenges associated with treatment for opioid use disorder during the COVID-19 pandemic. Dr. Lu describes the communities hardest hit by the COVID-19 pandemic and how the pandemic paved the way for regulation updates regarding buprenorphine treatment such as reduced restrictions and an increased use of telemedicine to treat opioid use disorders. The webinar also addresses some other measures put in place with buprenorphine treatment due to the public health emergency, including: longer prescriptions, halted urine drug testing (self reports), access to naloxone and harm reduction supplies. The presenter also shares available resources to support clinical providers as they face the challenges associated with buprenorphine treatment during the COVID-19 pandemic.
Participants will be able to:
- Explain regulatory updates regarding buprenorphine treatment during a public health emergency
- Describe practice-level changes in buprenorphine treatment throughout COVID-19
- Discuss common issues affecting patients in buprenorphine treatment during COVID-19
